Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Data was recently presented in an oral plenary at the 2026 MHNCS. Approximately 73K patients are diagnosed with head and neck cancer in the U.S. annually.1 The current standard of care for R/M HNSCC patients, based on the registrational KE.

Business Wire • 13 hours ago

Alger SICAV - Alger Dynamic Opportunities Fund Q4 2025 Portfolio Update

For the quarter, Alger SICAV - Alger Dynamic Opportunities Fund portfolio's average long exposure was 80.88% and the average short exposure was -32.28%. Long positions MongoDB, Inc., Natera, Inc., and Alphabet Inc. were among the top contributors to performance. Long positions Meta Platforms Inc., Nebius Group, and Roblox Corp. were among the top detractors from performance.

Seeking Alpha • 5 hours ago

Unveiling Natera (NTRA) Q4 Outlook: Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Natera (NTRA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.

Zacks Investment Research • Feb 23, 2026

Billionaire Stanley Druckenmiller Is Betting Big on These 2 Stocks

One investment is a fast-growing genetic testing company that's now generating cash flow and has a scalable business model. The leading semiconductor foundry's sales are booming on AI-led demand, but expanding cash-flow margins will be a challenge.

The Motley Fool • Feb 22, 2026

Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions

Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions

Seeking Alpha • Feb 20, 2026

Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2025, after the market closes on Feb. 26, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's Fourth Quarter & Full Year 2025 Financial Results Date: February 26, 2026 Time: 1:30 p.m.

Business Wire • Feb 17, 2026

Alger Mid Cap Growth Fund Q4 2025 Portfolio Update

Class A shares of the Alger Mid Cap Growth Fund outperformed the Russell Midcap Growth Index during the fourth quarter of 2025. Cidara Therapeutics, Inc., Natera, Inc., and Abivax were among the top contributors to performance. Roblox Corp. Class A, e.l.f. Beauty, Inc., and Nebius Group were among the top detractors from performance.

Seeking Alpha • Feb 17, 2026

Allspring Growth Fund Q4 2025 Fund Performers And Detractors

Carpenter Technology Corp. multiple long-term contracts were repriced favorably as airlines keep aging fleets in service longer driving higher maintenance needs. Natera, Inc. doubled the number of oncology sales representatives to drive awareness and volumes in 2026. Natera, Inc. doubled the number of oncology sales representatives to drive awareness and volumes in 2026.

Seeking Alpha • Feb 13, 2026

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of EDEN, a large, multi-center prospective study designed to evaluate the company's non-invasive prenatal screening test for early risk assessment of preeclampsia and other serious pregnancy complications. Preeclampsia affects approximately 5-8% of pregnancies and remains a leading cause of maternal and neonatal morbidity.1 While clinical guidelines re.

Business Wire • Feb 6, 2026

Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test

NTRA submits FDA PMA for Signatera CDx, aiming to guide bladder cancer treatment with MRD testing after positive phase 3 trial results.

Zacks Investment Research • Feb 3, 2026